Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Immuron's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Immuron's regulatory disclosures and financial reporting.
Immuron Limited has completed its small holding share sale facility, buying back 3,805,528 ordinary shares at $0.032 per share, for an aggregate value of $121,777. These shares will be cancelled.
The facility targeted shareholders holding less than a marketable parcel, defined under ASX rules as shares worth under $500 based on the 8 April 2026 record date price. Eligible shareholders could opt out or top up their holdings; those who did not became participating shareholders whose shares were acquired under the buy-back.
Following completion, Immuron’s ordinary shares on issue decreased from 326,653,609 to 322,848,081, and the number of shareholders fell from 2,264 to 1,253. The company expects this to lower ongoing administrative costs associated with managing many very small holdings.
Immuron Limited filed a Form 6-K noting the expiry of a tranche of options listed on the ASX. On 18 June 2026, 1,430,000 IMCAI options expiring on various dates and at various exercise prices ceased after expiring without being exercised or converted, and no consideration was paid for the cessation.
Following this lapse, Immuron reports issued capital of 326,653,609 ordinary fully paid shares, along with 3,767,492 performance rights and 8,000,000 IMCAI options still on issue, as recorded in the ASX-generated tables.
Immuron Limited furnished a Form 6-K providing its response to an ASX price query about recent trading in its securities. The company states it is not aware of any information that has not been announced which would explain the price movements and confirms it remains in compliance with ASX Listing Rule 3.1 on continuous disclosure. The response notes a previously disclosed CEO presentation at the Emerging Growth Conference and has been authorised by the Board of Directors.
Immuron Ltd executive Flavio Palumbo has filed an initial ownership report showing his equity interests in the company. He directly holds 1,142,909 Ordinary Shares. He also holds 640,824 Performance Rights, each linked to Ordinary Shares, with a zero exercise price and an expiration date of June 30, 2029. These performance rights vest only when specified non-market key performance indicators and performance milestones are achieved, after which they can be exercised any time until expiration.
Immuron Ltd director Daniel Jude Pollock has filed an initial Form 3 showing his share and option holdings. He reports direct ownership of 568,750 Ordinary Shares and an additional 174,480 Ordinary Shares held indirectly through joint ownership with his spouse. Pollock also holds options over 1,000,000 Ordinary Shares with a USD exercise price of $0.0789 expiring on October 3, 2029, and options over 333,333 Ordinary Shares with a USD exercise price of $0.1040 expiring on August 20, 2028. Footnotes explain these option grants vest in staged annual installments and that the exercise prices were originally denominated in Australian dollars and translated into U.S. dollars using an exchange rate of AUD 1.00 = USD 0.7172.
Immuron Limited used this report to share an investor presentation highlighting its oral immunotherapy focus, commercial products and partnering strategy. The company sells Travelan for traveler’s diarrhea and ProIBS for irritable bowel syndrome, while developing pipeline assets IMM-124E and IMM-529 for infectious gut diseases.
Management plans to partner IMM-124E and IMM-529 so licensees fund clinical development and commercialization in exchange for upfront fees, milestones and royalties. Immuron reported FY26 year-to-date global sales revenue of A$5.7 million, third-quarter revenue of A$1.5 million, and cash of A$10.0 million as of December 31, 2025, supporting its over-the-counter business.
Immuron Ltd director and Chairman of the Board Paul Gerard Brennan filed an initial Form 3 detailing his option holdings in the company. He holds options over 1,000,000 Ordinary Shares at an exercise price of $0.0789 per share, expiring on October 3, 2029, and options over 666,667 Ordinary Shares at an exercise price of $0.1793 per share, expiring on November 21, 2027. Footnotes explain that these options vest in staged annual installments between November 24, 2024 and November 24, 2028, with portions becoming exercisable each year as service-based vesting conditions are met. The exercise prices were originally set in Australian dollars and translated into U.S. dollars using a Reserve Bank of Australia exchange rate.
Immuron Limited filed a Form 6-K to share an Australian Securities Exchange announcement that its CEO, Steven Lydeamore, will present virtually at the Emerging Growth Conference on 7 May 2026 from 10:15am to 10:45am U.S. Eastern Time. The notice includes registration and question-submission details for the event.
The accompanying presentation materials describe Immuron’s focus on orally delivered, targeted polyclonal antibodies for infectious diseases and highlight key products, including Travelan® for travelers’ diarrhea, investigational candidate IMM-529 for recurrent C. difficile infection, and ProIBS® for irritable bowel syndrome symptoms.
Immuron Ltd Chief Scientific Officer Jerry Kanellos filed an initial ownership report showing his existing equity position. He directly holds 333,000 Ordinary Shares of Immuron.
He also holds Performance Rights over 272,134 underlying Ordinary Shares with a 0.0000 exercise price expiring on June 30, 2029, and additional Performance Rights over 179,664 underlying Ordinary Shares with a 0.0000 exercise price expiring on July 12, 2027. A footnote states these Performance Rights became exercisable as to 217,707 shares on July 23, 2025 and 54,427 shares on October 29, 2025.
Immuron Ltd filed an initial statement of beneficial ownership on Form 3 for Aaron James Laurita, who serves as Chief Financial Officer. The filing does not report any share transactions or holdings in either common stock or derivative securities, indicating this is a baseline regulatory disclosure as he becomes a reporting insider.